Drug details

Erwinaze (asparaginase erwinia chrysanthemi)

type of Enzymes, Oncology

Erwinaze (asparaginase Erwinia chrysanthemi) is indicated for the treatment of acute lymphoblastic leukemia (ALL) patients who have developed an allergy (hypersensitivity) to E. coli derived asparaginase and pegaspargase chemotherapy drugs used to treat ALL.

This drug may have the following side effects:

• nausea
• diarrhea
• vomiting
• serious allergic reactions (anaphylaxis)
• inflammation of the pancreas (pancreatitis)
• high blood levels of liver enzymes (abnormal transaminases and bilirubin)
• blood clotting
• bleeding (hemorrhage)
• stomach pain, and
• high blood sugar (hyperglycemia)

The following drugs are related to Erwinaze, either as a replacement or used together:

• Rylaze (asparaginase erwinia chrysanthemi (recombinant) - rywn) injection)
• Symbenda (bendamustine hydrochloride)
• Myleran Tablets (busulfan tablets)
• Cerubidine (daunorubicin)
• Leustatin (cladribine injection for intravenous infusion only)
• Cytoxan (cyclophosphamide)
• Nivestym (filgrastim-aafi injection)
• Idamycin (idarubicin)
• Idamycin PFS (idarubicin hydrochloride injection)
• Purinethol (mercaptopurine)
• Tasigna Capsules (nilotinib capsules)
• Oncaspar (pegaspargase)